Product Reports Resources Pricing Login Book a demo

Immunai

Biotech & Life Sciences · New York City, United States · Founded 2019

Mapping and reprogramming the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development, and improve patient outcomes

Investors

15 investors on Immunai's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Series A 4 investors entered at this stage
Dexcel Pharma
Schusterman Foundation
Catalio Capital Management
Duquesne Family Office
Series B+ 9 investors entered at this stage
Stanford University
Koch Disruptive Technologies
Icon Ventures
Parker Institute for Cancer Immunotherapy
Alexandria Venture Investments
Talos
8VC
Piedmont Healthcare
Massachusetts Institute of Technology

Global footprint

Where Immunai has talent and traffic

Workforce by country
8 countries with
team presence
🇮🇱 Israel42%
🇺🇸 United States39.4%
🇨🇿 Czech Republic12%
🇨🇭 Switzerland3.9%
🇩🇪 Germany1.1%
Top 5 of 8 shown
Web traffic by country
6.4K monthly visits
across markets
🇺🇸 United States67.2%
🇮🇳 India18.8%
🇮🇱 Israel12.5%
🇩🇪 Germany1.6%
Top 4 markets shown

Talent graph

The shape of Immunai's talent

Dealroom maps Immunai's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

16 standout operatorsDealroom-flagged across the org
20 AI specialistsincl. 11 core researchers
176 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Immunai's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$90k patent portfolio · 3 active families

Estimated portfolio value
$90k
<0.01% of valuation · 90.8× smaller than top peer Sophia Genetics ($8M)
3 active patent families

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Immunai

An AI-synthesized read of the highest-engagement posts about Immunai on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immunai on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.